| Original language | English (US) |
|---|---|
| Article number | 37 |
| Journal | Blood cancer journal |
| Volume | 11 |
| Issue number | 2 |
| DOIs | |
| State | Published - Feb 2021 |
ASJC Scopus subject areas
- Hematology
- Oncology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Blood cancer journal, Vol. 11, No. 2, 37, 02.2021.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Upregulation of AXL and β-catenin in chronic lymphocytic leukemia cells cultured with bone marrow stroma cells is associated with enhanced drug resistance
AU - Sinha, Sutapa
AU - Secreto, Charla R.
AU - Boysen, Justin C.
AU - Lesnick, Connie
AU - Wang, Zhiquan
AU - Ding, Wei
AU - Call, Timothy G.
AU - Kenderian, Saad J.
AU - Parikh, Sameer A.
AU - Warner, Steven L.
AU - Bearss, David J.
AU - Ghosh, Asish K.
AU - Kay, Neil E.
N1 - Funding Information: Supported in part by Tolero Pharmaceuticals Inc., Mayo Clinic intramural funding, AKG grant CA170006, and supported in part by the Henry J. Predolin Foundation. Funding Information: S.S., C.R.S., J.C.B., C.L., Z.W., T.G.C., and A.K.G.—No conflicts. S.L.W. and D.J.B.— Employed by Tolero, developer of TP-0903. S.J.K.—S.J.K. is an inventor on patents in the field of CART cell therapy that are licensed to Novartis, Humanigen, and Mettafore. S.J.K. receives research funding from Kite, Gilead, Juno, BMS, Morphosys, Sunesis, leahlabs, Lentigen, Humanigen, and Tolero. S.J. K. is on the DSMB of Humanigen. S.J.K. is on scientific advisory boards for Humanigen, Kite, and Juno. S.A.P.—Research funding has been provided to the institution from Pharmacyclics, MorphoSys, Janssen, AstraZeneca, TG Therapeutics, Bristol Myers Squibb, Merck, AbbVie, and Ascentage Pharma for clinical studies in which S.A.P. is a principal investigator. S.A.P. has also participated in Advisory Board meetings of Pharmacyclics, AstraZeneca, Genentech, Gilead, GlaxoSmithKline, Verastem Oncology, and AbbVie (he was not personally compensated for his participation). W.D.—Research funding from Merck, DTRM, Astrazeneca, and Abbvie, advisory board for Merck, Octapharma, MEI pharma, Alexion, and Beigene. N.E.K.—Abbvie, Astra Zeneca, Cytomx Therapy, Dava oncology, Juno Theraputics, Oncotracker, Pharmacyclics. DSMC (Data Safety Monitoring Committee) for: Agios Pharm, AstraZeneca, BMS-Celgene, Cytomx Therapeutics, Morpho-sys, Rigel. Research funding from: Abbvie, Acerta Pharma, Bristol Meyer Squib, Celgene, MEI Pharma, Pharmacyclics, Sunesis, TG Therapeutics, and Tolero Pharmaceuticals.
PY - 2021/2
Y1 - 2021/2
UR - http://www.scopus.com/inward/record.url?scp=85101205746&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85101205746&partnerID=8YFLogxK
U2 - 10.1038/s41408-021-00426-2
DO - 10.1038/s41408-021-00426-2
M3 - Letter
C2 - 33602892
AN - SCOPUS:85101205746
SN - 2044-5385
VL - 11
JO - Blood cancer journal
JF - Blood cancer journal
IS - 2
M1 - 37
ER -